eligibility_summary
Include: consented adults ≥18 with severe eosinophilic asthma ≥6 mo, benralizumab-eligible (NICE), poorly controlled (ACQ-6>1.5), FeNO ≥50 ppb despite high-dose ICS (≥1000 mcg BDP eq), ≥50% with adult-onset. Exclude: other eosinophilic lung disease, maintenance OCS, severe bronchiectasis, current/≥20 pack-yr smoking, SpO2<94%, comorbidity making bronchoscopy/sedation high risk, recent infection/exacerbation/steroid change (<3 wks), +strongyloides, pregnancy/lactation, benralizumab allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: Benralizumab, a humanized monoclonal antibody biologic given subcutaneously for severe eosinophilic asthma. Mechanism: binds IL-5 receptor alpha (IL-5Rα) on eosinophils (and basophils), triggering rapid cytotoxic depletion and reducing airway inflammation. Cells/pathways targeted: primary depletion of eosinophils/basophils, downstream modulation of type-2 (T2) inflammatory pathways and mediators (IL-5, IL-4, IL-13), including the IL-13/FeNO axis, potential effects on ILC2s, bronchial epithelial cells, alveolar macrophages, mast cells, and airway smooth muscle, exploratory restoration of antiviral responses (e.g., rhinovirus/SARS-CoV-2).